Leukotriene-receptor antagonists: Role in asthma management

Canadian Family Physician

Volumn 46, Issue APR., 2000, Pages 872-884

  D'Urzo, Anthony D ^a   Chapman, Kenneth R ^b  

^a Primary Care Asthma Clinic   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; ERYTHROMYCIN; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ORAL CONTRACEPTIVE AGENT; RIFAMPICIN; TERFENADINE; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE CALCULATION; DRUG COMPETITION; DRUG DISPOSITION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; REVIEW;

ACETATES; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL SPASM; CHRONIC DISEASE; DOUBLE-BLIND METHOD; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY THERAPY; TIME FACTORS; TOSYL COMPOUNDS;

EID: 0034065272     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Burney PGJ. Epidemiologic trends. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Philadelphia, Pa: Lippincott-Raven Publishers; 1997. p. 35-47.
2. Ernst P, Fitzgerald MJ, Spier S. Canadian Asthma Consensus Conference Summary of Recommendations. Can Respir J 1996;3(2):89-100.
3. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96(5 pt 1):571-9.
4. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337(1): 8-14.
5. Henderson WR Jr. Eicosanoids and platelet-activating factor in allergic respiratory diseases. Am Rev Respir Dis 1991; 143(5 Pt 2):S86-90.
6. Samuelson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
7. Drazen JM. Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 1986;89:414-9.
8. Rinkema LE, Bemis KG, Fleisch JH. Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes and AXZ3187. J Pharmacol Exp Ther 1984;230:550-7.
9. Spector SL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995;75(6):463-73.
10. 4: biologic properties and regulation of biosynthesis. In: Piper PJ, editor. The leukotrienes: their biological significance. New York, NY: Raven Press; 1986. p. 141-50.
11. 4, and histamine in normal human subjects. Thorax 1984;39:500-4.
12. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991;144:1053-7.
13. O'Bryne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740-51.
14. 4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990;86:211-20.
15. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-8.
16. Taylor GW, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet 1991;337:690-4.
17. 4 receptor blockage inhibits the immediate and late bronchoconstrictor response to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
18. Friedman BS, Bel EH, Buntinx, Tanaka W, Han YH, Shingo S, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir 1993;147(4):839-44.
19. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
20. 1- receptor antagonist, on eosinophil counts and ECP in induced sputum before and after allergen challenge in asthmatics. Eur Respir J. In press.
21. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E Jr, Reed CE, Middleton E, Reed CE, Ellis EF, Adkinson NF, et al, editors. Allergy: principles and practice. St Louis, Mo: CV Mosby; 1993. p. 1747-65.
22. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK & F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
23. Dahlen B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, et al. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
24. 2 receptor antagonist, improves asthma control in aspirin intolerant asthmatic patients. Am J Respir Crit Care Med 1996;153(4 Pt 2):A975.
25. 4 receptor antagonist. Am Rev Respir Dis 1992;145: 746-9.
26. Leff JA, Busse WW, Pearlman D, Bronsky E, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist for the treatment of mild asthma and exercise induced bronchoconstriction. N Engl J Med 1998;339(3):147-82.
27. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;339(3):141-6.
28. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicentre, randomized, double-blind trial. Arch Intern Med 1998;158:1213-20.
29. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
30. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6 to 14 year old children. JAMA 1998;279:1181-6.
31. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma. Eur Respir J 1998;11:1232-9.
32. Lofdahl CG, Reiss TF, Leff AJ, Isreal E, Noonan JM, Finn AF, et al. Randomized, placebo-controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
33. Leff JA, Pizzichini E, Efthimaiadis A, Boulet LP, Wei LX, Weinland DE, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial [abstract]. Am J Respir Crit Care Med 1997;155:A977.
34. Malmstrom K, Guerra J, Rodrequez-Gomez G, Billaran C, Pineiro A, Gazzillo A, et al. A comparison of montelukast, a leukotriene receptor antagonist and inhaled beclomethasone in chronic asthma. Ann Intern Med 1999;130:487-95.
35. 4 antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
36. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicentre study. Clin Ther 1997;19(4):675-90.
37. Micheletto C, Turco P, Dal Negro R. Accolate 20 mg works as steroid sparing in moderate asthma [abstract]. Am J Respir Crit Care Med 1997;155:A664.
38. Kylstra JW, Sweitzer DE, Miller CJ, Bonuccelli CM. Zafirlukast (Accolate) in moderate asthma: patient-reported outcomes and peripheral eosinophil data from a 13-week trial [abstract]. Am J Respir Crit Care Med 1998;157:A410.
39. Singulair (montelukast sodium) [product monograph]. Kirkland, Que: Merck Frosst Canada Inc; June 15, 1998.
40. Accolate (zafirlukast) [product monograph]. Mississauga, Ont: Zeneca Pharma Inc; 1997.